Loading company…
Riskpilot
← Back to search
Sign in
Get full access
ReceptorPharma AB
AB
Bankrupt
Org 5591329833
Other research and experimental development on natural sciences and engineering · NACE 7219
Est. 2017
1 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2020
SEK 0
EBITDA margin
—
+20% vs 2019
Equity ratio
-3161.1%
Financial strength
Net profit 2020
SEK -179K
+20% vs 2019
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2018
0M
0%
2019
0M
0%
2020
Key figures
Annual report 2020
Revenue
SEK 0
—
EBITDA
SEK -178K
+20%
Net profit
SEK -179K
+20%
Total assets
SEK 18K
-31%
Equity
SEK -569K
-46%
Employees
1
—
Company information
Legal name
ReceptorPharma AB
Org number
5591329833
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
8 november 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget skall bedriva forskning inom kemi samt därmed förenlig verksamhet.
Contact
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Other research and experimental development on natural sciences and engineering
Companies in
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2018
0M
2019
0M
2020
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2018
0M
2019
0M
2020
Income statement
SEK thousands
Item
2018
2019
2020
Revenue
—
0
0
Staff expenses
—
—
—
EBITDA
0
−223
−178
Depreciation & amort.
—
−0
−0
EBIT
0
−223
−178
Net financials
—
—
−1
Profit before tax
0
−223
−179
Tax
—
−0
−0
Net profit
—
−223
−179
Balance sheet
SEK thousands
Item
2018
2019
2020
Total assets
—
26
18
Equity
—
−390
−569
Long-term debt
—
0
0
Short-term debt
—
415
587
Total debt
—
415
587
Financial ratios
5-year trend
EBITDA margin
-17800000.0%
This company
15.8%
Market median
-112658328% vs market
2018
2020
Equity ratio
-3161.1%
This company
38.2%
Market median
-8375% vs market
2018
2020
Return on equity
-17900000.0%
This company
18.4%
Market median
-97282709% vs market
2018
2020
Net profit margin
-17900000.0%
This company
8.1%
Market median
-220987754% vs market
2018
2020
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2018
2020
Debt / equity
1.03×
This company
0.62×
Market median
-66% vs market
2018
2020
Annual reports & filings
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
View
PDF
Annual report 2018
Filed via Bolagsverket / SCB · Period 2017-11-01 – 2018-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
HR
Hans Roland Charlie Jensen
Liquidator
Liquidator
2020
Board of directors
Non-executive oversight
Name
Role
Member since
Former (2)
SB
Stefan Broselid
Chairman
2020 – 2022
JA
Johanna Anna Linnea Österberg
Deputy Board Member
2020 – 2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of ReceptorPharma AB also hold positions in
0
other companies.
Person
Role here
Other companies
Hans Roland Charlie Jensen
Liquidator
0 companies
Stefan Broselid
Chairman
0 companies
Johanna Anna Linnea Österberg
Deputy Board Member
0 companies